Thousands of children, families, and communities will have the opportunity to learn to fish with national park rangers at more than 50 national parks.WASHINGTON,...
PERTH, Australia, June 9, 2026 /PRNewswire/ -- New Frontier Minerals Limited (ASX: NFM; OTCQB: NFMXF) announced it is commencing characterization and metallurgical studies at...
LOS ANGELES, June 9, 2026 /PRNewswire/ -- As summer temperatures begin to climb across the United States, many households are placing greater emphasis on...
Peak Power appoints Doran Hole and Benjamin Baker to its Board of Directors to accelerate battery storage and grid flexibility growth across North America.
CSE: BARFWB:314OTCQB: BRGMFVANCOUVER, BC, June 9, 2026 /PRNewswire/ - Barranco Gold Mining Corp. ("Barranco" or the "Company") is pleased to announce that it has engaged Rio...
New Harris Poll research of more than 3,000 U.S. adults finds Eagle Scouts report 2x lower loneliness, significantly higher purpose and leadership and stronger...
CSE: BARFWB:314OTCQB: BRGMFVANCOUVER, BC, June 9, 2026 /CNW/ - Barranco Gold Mining Corp. ("Barranco" or the "Company") is pleased to announce that it has engaged Rio...
Dallas, TX, June 09, 2026 (GLOBE NEWSWIRE) -- Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse, and remediation services, today announced financial and operational results for the three months ended March 31, 2026.
Agreement with Selagine, Inc. supports the development of an investigational pooled plasma biologic platform intended to move beyond individualized compounded serum tearsCHICAGO, June 9,...
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma
- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers